Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452863 | 0.78 | TSHR (0.37) | — | |
| SCHEMBL7503891 | 0.76 | MAPT (0.33) | — | |
| SCHEMBL6048743 | 0.74 | CTSK (0.33) | — | |
| SCHEMBL3531184 | 0.74 | MAPT (0.34) | THRB | |
| SCHEMBL456197 | 0.73 | MEN1 (0.48) | THRB | |
| SCHEMBL17501746 | 0.72 | THRB (0.50) | THRB | |
| SCHEMBL221073 | 0.72 | PTPN1 (0.40) | THRB | |
| SCHEMBL8404113 | 0.72 | CHRM1 (0.34) | — | |
| SCHEMBL6829768 | 0.72 | MEN1 (0.38) | THRB | |
| SCHEMBL8306724 | 0.71 | MEN1 (0.47) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034094-B1 | PHOSPHODIESTERASE INHIBITORS AND USE | ZENSHINE PHARMACEUTICALS NANJING GROUP CO LTD (CN) | 2026-04-15 | — | — | EP | disclosed |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| EP-4034094-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. (CN) | 2022-08-03 | — | — | EP | disclosed |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| WO-2021061803-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2021-04-01 | — | — | WO | disclosed |
| EP-1427508-B1 | HELIUM RECOVERY | PRAXAIR TECHNOLOGY INC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7294172-B2 | Helium recovery | PRAXAIR TECHNOLOGY, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1427508-A4 | HELIUM RECOVERY | PRAXAIR TECHNOLOGY INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040237789-A1 | Helium recovery | PRAXAIR TECHNOLOGY, INC. | 2004-12-02 | — | — | US | disclosed |
| EP-1427508-A1 | HELIUM RECOVERY | PRAXAIR TECHNOLOGY, INC. (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-0960099-B1 | IMPROVED PROCESS FOR THE PREPARATION OF HALO-4-PHENOXYQUINOLINES | DOW AGROSCIENCES LLC (US) | 2003-04-16 | — | — | EP | disclosed |
| WO-2003011431-A1 | HELIUM RECOVERY | PRAXAIR TECHNOLOGY, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-6475265-B1 | Pressure swing adsorption method for production of an oxygen-enriched gas | PRAXAIR TECHNOLOGY, INC. | 2002-11-05 | — | — | US | disclosed |
| EP-0960099-A1 | IMPROVED PROCESS FOR THE PREPARATION OF HALO-4-PHENOXYQUINOLINES | Dow AgroSciences LLC (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5973153-A | Process for the preparation of halo-4-phenoxyquinolines | DOWELANCO LLC | 1999-10-26 | — | — | US | disclosed |
| WO-1998033774-A1 | IMPROVED PROCESS FOR THE PREPARATION OF HALO-4-PHENOXYQUINOLINES | DOW AGROSCIENCES LLC (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | ENPP1, ENPP3, PDE4A | THRB 4673/4885 |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | ENPP1, ENPP3, PDE4A | THRB 3812/4885 |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | ENPP1, ENPP3, PDE4A | THRB 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.